Related Experiment Video
Updated: Mar 8, 2026

A Protocol for Rapid Post-mortem Cell Culture of Diffuse Intrinsic Pontine Glioma DIPG
Published on: March 7, 2017
Insulin-Mediated Signaling Facilitates Resistance to PDGFR Inhibition in Proneural hPDGFB-Driven Gliomas
Damian A Almiron Bonnin1,2, Cong Ran1,2, Matthew C Havrda1,2
1Department of Molecular and Systems Biology, Geisel School of Medicine at Dartmouth, Hanover, New Hampshire.
Abstract:
Despite abundant evidence implicating receptor tyrosine kinases (RTK), including the platelet-derived growth factor receptor (PDGFR), in the pathogenesis of glioblastoma (GBM), the clinical use of RTK inhibitors in this disease has been greatly compromised by the rapid emergence of therapeutic resistance. To study the resistance of proneural gliomas that are driven by a PDGFR-regulated pathway to targeted tyrosine kinase inhibitors, we utilized a mouse model of proneural glioma in which mice develop tumors that become resistant to PDGFR inhibition. We found that tumors resistant to PDGFR inhibition required the expression and activation of the insulin receptor (IR)/insulin growth-like factor receptor (IGF1R) for tumor cell proliferation and survival. Cotargeting IR/IGF1R and PDGFR decreased the emergence of resistant clones in vitro Our findings characterize a novel model of glioma recurrence that implicates the IR/IGF1R signaling axis in mediating the development of resistance to PDGFR inhibition and provide evidence that IR/IGF1R signaling is important in the recurrence of the proneural subtype of glioma in which PDGF/PDGFR is most commonly expressed at a high level. Mol Cancer Ther; 16(4); 705-16. ©2017 AACR.
Insights
Therapeutic resistance in glioblastoma (GBM) involves insulin receptor (IR)/insulin growth-like factor receptor (IGF1R) signaling. Targeting IR/IGF1R alongside PDGFR may overcome resistance to receptor tyrosine kinase inhibitors.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Therapeutics
Background:
- Receptor tyrosine kinases (RTKs), including platelet-derived growth factor receptor (PDGFR), are implicated in glioblastoma (GBM) pathogenesis.
- Therapeutic resistance to RTK inhibitors is a major clinical challenge in treating GBM.
Purpose of the Study:
- To investigate the mechanisms of therapeutic resistance in proneural gliomas driven by PDGFR signaling.
- To identify alternative therapeutic targets to overcome resistance to PDGFR inhibition.
Main Methods:
- Utilized a genetically engineered mouse model of proneural glioma that develops resistance to PDGFR inhibition.
- Assessed the role of insulin receptor (IR)/insulin growth-like factor receptor (IGF1R) signaling in resistant tumor cells.
- Evaluated the efficacy of cotargeting IR/IGF1R and PDGFR in vitro.
Main Results:
- Tumors resistant to PDGFR inhibition showed dependence on IR/IGF1R signaling for proliferation and survival.
- Cotargeting IR/IGF1R and PDGFR significantly reduced the emergence of resistant clones in vitro.
Conclusions:
- The IR/IGF1R signaling axis is a key mediator of resistance to PDGFR inhibition in a subset of gliomas.
- IR/IGF1R signaling is crucial for glioma recurrence, particularly in the proneural subtype.
- Combined inhibition of IR/IGF1R and PDGFR presents a potential strategy to overcome therapeutic resistance in GBM.
More Related Videos
12:52Isolation and Flow Cytometric Analysis of Glioma-infiltrating Peripheral Blood Mononuclear Cells
Published on: November 28, 2015
10:58Transposon Mediated Integration of Plasmid DNA into the Subventricular Zone of Neonatal Mice to Generate Novel Models of Glioblastoma
Published on: February 22, 2015
Related Concept Videos
Insulin: The Receptor and Signaling Pathways
PI3K/mTOR/AKT Signaling Pathway
Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Regulation of Angiogenesis and Blood Supply